Luca Issi is ranked #743 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

RBC

Luca Issi

Q: How accurate are Luca Issi's stock ratings?

About 62% of Luca's ratings were profitable over a one-year hold, with an average return of +6.5% per rating, measured by 13Foresight from historical prices.

RBC Capital

Wall Street Analyst

★★★★☆

#743

on 13Foresight · ranked by our own returns

62%

Success Rate

+6.5%

Average Return

40 of 65 calls profitable · +2.8% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 62% of Luca Issi's ratings turned a profit when each position was held for 1 year — averaging +6.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

110 Buy 58 Hold 0 Sell

Luca's Stock Coverage 29 ratings · 2026-08-13

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
BBIO BridgeBio Pharma	Aug 10, 2026	BUY	Strong Buy +12.8% avg upside 34 analysts	$100.00 18.16% Upside	-4.1%	·
KRRO Korro Bio	Aug 07, 2026	HOLD	Strong Buy +104.1% avg upside 19 analysts	$10.00 24.37% Downside	+0.3%	·
BMRN BioMarin Pharmaceutical	Aug 07, 2026	HOLD	Strong Buy +35.2% avg upside 52 analysts	$62.00 12.22% Downside	+7.4%	·
RGNX RegenXBio	Aug 06, 2026	BUY	Strong Buy +246.5% avg upside 22 analysts	$19.00 71.76% Upside	-5.5%	·
NTLA Intellia Therapeutics	Aug 06, 2026	HOLD	Buy +220.1% avg upside 37 analysts	$15.00 24.08% Upside	+5.2%	·
ARWR Arrowhead Pharmaceuticals	Aug 05, 2026	BUY	Strong Buy -14.4% avg upside 27 analysts	$100.00 12.25% Upside	+0.4%	·
BEAM Beam Therapeutics	Aug 05, 2026	HOLD	Strong Buy +94.3% avg upside 25 analysts	$26.00 3.46% Downside	-2.1%	·
EDIT Editas Medicine	Aug 05, 2026	HOLD	Buy +373.3% avg upside 33 analysts	$4.00 39.36% Upside	+2.2%	·
RARE Ultragenyx Pharmaceutical	Aug 05, 2026	BUY	Strong Buy +147.8% avg upside 36 analysts	$40.00 49.53% Upside	+5.8%	·
AMGN Amgen	Aug 05, 2026	BUY	Buy -24.2% avg upside 57 analysts	$400.00 4.17% Downside	+2.5%	·
CRSP Crispr Therapeutics AG	Aug 03, 2026	HOLD	Buy +40.0% avg upside 41 analysts	$50.00 7.16% Downside	+8.9%	·
MRNA Moderna	Jul 31, 2026	HOLD	Hold +11.9% avg upside 38 analysts	$45.00 29.38% Downside	+16.1%	·
ALNY Alnylam Pharma	Jul 30, 2026	BUY	Strong Buy +44.8% avg upside 51 analysts	$350.00 58.12% Upside	+10.5%	·
AGIO Agios Pharma	Jul 30, 2026	HOLD	Strong Buy +84.3% avg upside 29 analysts	$32.00 5.65% Downside	+2.2%	·
WVE Wave Life Sciences	Jul 30, 2026	BUY	Strong Buy +299.0% avg upside 28 analysts	$15.00 179.41% Upside	-9.7%	·
IONS Ionis Pharmaceuticals	Jul 29, 2026	BUY	Strong Buy +40.4% avg upside 43 analysts	$85.00 49.93% Upside	+5.4%	·
DYN Dyne Therapeutics	Jul 29, 2026	BUY	Strong Buy +51.5% avg upside 31 analysts	$35.00 31.97% Upside	+3.4%	·
QURE uniQure	Jul 29, 2026	BUY	Strong Buy +31.0% avg upside 29 analysts	$65.00 43.64% Upside	+17.4%	·
GB:0QW0 arGEN X	Jul 23, 2026	BUY	Strong Buy -19.1% avg upside 24 analysts	—	·	·
ARGX Argenx Se	Jul 23, 2026	BUY	Strong Buy -10.3% avg upside 47 analysts	$1025.00 16.94% Upside	-7.3%	·
ASND Ascendis Pharma	Jul 07, 2026	BUY	Strong Buy +8.1% avg upside 24 analysts	$280.00 8.62% Upside	-7.8%	·
FULC Fulcrum Therapeutics	Jun 02, 2026	HOLD	Hold +137.5% avg upside 14 analysts	$4.00 7.65% Upside	+18.1%	·
SGMOQ Sangamo Therapeutics	May 14, 2026	HOLD	Buy +7188.3% avg upside 16 analysts	$2.00 1189.46% Upside	-21.4%	·
ALLO Allogene Therapeutics	May 13, 2026	BUY	Strong Buy +630.3% avg upside 28 analysts	$9.00 323.62% Upside	-15.0%	·
LXEO Lexeo Therapeutics, Inc.	May 11, 2026	BUY	Strong Buy +295.1% avg upside 11 analysts	$20.00 299.11% Upside	-18.9%	·
CRBU Caribou Biosciences	May 08, 2026	BUY	Strong Buy +561.9% avg upside 12 analysts	$10.00 495.18% Upside	-17.0%	·
MGTX Meiragtx Holdings	Nov 13, 2024	BUY	Strong Buy +100.6% avg upside 13 analysts	$11.00 15.11% Downside	+17.3%	·
QTTB Q32 Bio	May 11, 2023	HOLD	Buy +288.0% avg upside 24 analysts	$54.00 251.98% Upside	+51.5%	·
LENZ LENZ Therapeutics	Mar 21, 2023	HOLD	Buy +306.3% avg upside 17 analysts	$3.00 46.94% Downside	+93.9%	·

🔒 24 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Luca Issi — Frequently Asked Questions

How accurate are Luca Issi's stock ratings?

Based on the calls 13Foresight could measure, about 62% of Luca's ratings were profitable over a one-year hold, with an average return of +6.5% per rating, or +2.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Luca ranked on 13Foresight?

Luca Issi is currently ranked #743 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Luca cover?

Luca most recently has ratings on BBIO, KRRO, BMRN, RGNX, NTLA, ARWR, BEAM, EDIT, RARE, AMGN, CRSP, MRNA and 17 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Luca Issi

Rating Distribution

Welcome to 13Foresight!